Skip to main content
Caplight Logo









ReBlood Rx

ReBlood Rx

Private
San Diego, CaliforniaHealthcare & Life Scienceshttps://rebloodrx.com/

Last Round

Grant

Jan 1, 2026

Total Funding Raised

$402,000

Momentum

Top 50%

of companies Caplight tracks

Company Overview

ReBlood Rx is a biotechnology company that develops hemoglobin-based oxygen carriers (HBOCs) to provide safe and efficient oxygen delivery solutions for medical emergencies.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices

Business Model

B2B

Customer Profile

Services & Consulting, Hardware Sales

AI Layer

Non-AI

Keywords

hemoglobin-based oxygen carrierHBOCblood substituteartificial bloodoxygen delivery systememergency medicineveterinary medicineshelf-stable bloodbiotechnologycombat casualty caremedical logisticstrauma careuniversal donor bloodcold-chain alternative

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ReBlood Rx Comparables

Compare ReBlood Rx with similar companies based on industry and business-model similarity.

ReBlood Rx comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
VirTech Bio
91%
KaloCyte, Inc.
84%
OxyVita Inc.
80%

ReBlood Rx Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJan 1, 2026
SeedAug 4, 2025
GrantAug 4, 2025
AcceleratorAug 19, 2024
GrantJul 1, 2024

ReBlood Rx Investors

Notable investors and investment history

ReBlood Rx investors
InvestorRounds
DIANAGrant
757 CollabAccelerator
757 AccelerateAccelerator
rpvSeed
National Science FoundationGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 30, 2026

    Monthly visitors increased 680% MoM, from 54 to 421.

  • Jan 1, 2026

    $107K grant received from DIANA.

ReBlood Rx Filings

Explore SEC and related filing metadata, where available.

ReBlood Rx filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about ReBlood Rx's valuation, stock price, and market status.

Is ReBlood Rx a public or private company?

ReBlood Rx is a private company.

What is the current stock price of ReBlood Rx?

ReBlood Rx is a private company with no public stock price. No recent secondary market data is available.

How much is ReBlood Rx worth (valuation)?

Valuation information for ReBlood Rx is not publicly available.

Can I buy ReBlood Rx stock?

ReBlood Rx shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was ReBlood Rx's last funding round?

ReBlood Rx's most recent funding round was Grant on January 1, 2026.

Who are the main investors in ReBlood Rx?

Key investors in ReBlood Rx include DIANA, 757 Collab, 757 Accelerate, rpv, National Science Foundation.

Will ReBlood Rx IPO soon?

No public IPO plans have been announced for ReBlood Rx.

How can I track ReBlood Rx secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor ReBlood Rx's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSan Diego, California
Employee Range2
Year Founded2023
Last FundingJan 1, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?